BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33166530)

  • 1. Antileishmanial efficacy and tolerability of combined treatment with non-ionic surfactant vesicle formulations of sodium stibogluconate and paromomycin in dogs.
    Miret JA; Moreno J; Nieto J; Carter KC; Mullen AB; Ambros L; Rodríguez C; San Andrés MI; González F
    Exp Parasitol; 2021 Jan; 220():108033. PubMed ID: 33166530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune responses of Leishmania donovani infected BALB/c mice following treatment with free and vesicular sodium stibogluconate formulations.
    Banduwardene R; Mullen AB; Carter KC
    Int J Immunopharmacol; 1997 Apr; 19(4):195-203. PubMed ID: 9373770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani.
    Carter KC; Mullen AB; Sundar S; Kenney RT
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3555-9. PubMed ID: 11709339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium stibogluconate resistance in Leishmania donovani correlates with greater tolerance to macrophage antileishmanial responses and trivalent antimony therapy.
    Carter KC; Hutchison S; Boitelle A; Murray HW; Sundar S; Mullen AB
    Parasitology; 2005 Dec; 131(Pt 6):747-57. PubMed ID: 16336728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.
    Sinha R; Roychoudhury J; Palit P; Ali N
    Antimicrob Agents Chemother; 2015 Jan; 59(1):344-55. PubMed ID: 25367907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy of free and non-ionic-surfactant vesicular formulations of paromomycin in a murine model of visceral leishmaniasis.
    Williams D; Mullen AB; Baillie AJ; Carter KC
    J Pharm Pharmacol; 1998 Dec; 50(12):1351-6. PubMed ID: 10052848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection.
    Carter KC; Baillie AJ; Mullen AB
    Clin Diagn Lab Immunol; 1999 Jan; 6(1):61-5. PubMed ID: 9874665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals.
    Nieto J; Alvar J; Mullen AB; Carter KC; Rodríguez C; San Andrés MI; San Andrés MD; Baillie AJ; González F
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2781-7. PubMed ID: 12936974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c mice.
    Roychoudhury J; Sinha R; Ali N
    PLoS One; 2011 Mar; 6(3):e17376. PubMed ID: 21423750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis.
    Carter KC; Sundar S; Spickett C; Pereira OC; Mullen AB
    Antimicrob Agents Chemother; 2003 May; 47(5):1529-35. PubMed ID: 12709318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of aminosidine (paromomycin) and sodium stibogluconate for treatment of canine leishmaniasis.
    Poli A; Sozzi S; Guidi G; Bandinelli P; Mancianti F
    Vet Parasitol; 1997 Aug; 71(4):263-71. PubMed ID: 9299695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice.
    Carter KC; Dolan TF; Alexander J; Baillie AJ; McColgan C
    J Pharm Pharmacol; 1989 Feb; 41(2):87-91. PubMed ID: 2568434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pentavalent antimony-mannan conjugate therapy of experimental visceral leishmaniasis.
    Roberts WL; Hariprashad J; Rainey PM; Murray HW
    Am J Trop Med Hyg; 1996 Oct; 55(4):444-6. PubMed ID: 8916804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of
    Özbilgin A; Çavuş İ; Kaya T; Yıldırım A; Harman M
    Turkiye Parazitol Derg; 2020 Mar; 44(1):12-16. PubMed ID: 32212583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis.
    Fortin A; Hendrickx S; Yardley V; Cos P; Jansen H; Maes L
    J Antimicrob Chemother; 2012 Nov; 67(11):2707-12. PubMed ID: 22782488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
    Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR
    Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sub-optimal dose of Sodium Antimony Gluconate (SAG)-diperoxovanadate combination clears organ parasites from BALB/c mice infected with antimony resistant Leishmania donovani by expanding antileishmanial T-cell repertoire and increasing IFN-gamma to IL-10 ratio.
    Haldar AK; Banerjee S; Naskar K; Kalita D; Islam NS; Roy S
    Exp Parasitol; 2009 Jun; 122(2):145-54. PubMed ID: 19422069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.
    Azevedo EG; Ribeiro RR; da Silva SM; Ferreira CS; de Souza LE; Ferreira AA; de Oliveira E Castro RA; Demicheli C; Rezende SA; Frézard F
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1551-60. PubMed ID: 24962630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental treatment with sodium stibogluconate of hamsters infected with Leishmania (Leishmania) chagasi and Leishmania (Leishmania) amazonensis.
    de Figueiredo EM; Costa e Silva J; Brazil RP
    Rev Soc Bras Med Trop; 1999; 32(2):191-3. PubMed ID: 10228371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.
    Hendrickx S; Van den Kerkhof M; Mabille D; Cos P; Delputte P; Maes L; Caljon G
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005620. PubMed ID: 28505185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.